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The initiative of the current study was the unexpected complete tumor regression of a 31 
patient with stage IV cutaneous metastatic melanoma, who suffered multifactorial sepsis 32 
syndrome during BOLD chemotherapy (Suppl. Fig. 1.). After targeted antibiotic treatment 33 
and combined complication-free chemotherapy, the patient's physical condition improved 34 
and-unexpectedly- the metastases disappeared. The patient has been asymptomatic and 35 
metastasis- free ever since the end of BOLD therapy. A significant decrease in the volume of 36 
the previously palpable axillary and abdominal metastases was observed already when BOLD 37 
was interrupted due to sepsis. For a timeline of events, see Table 1. 38 
Molecular genetics research in the last decade helped the development of BRAF 39 
inhibitors and immunooncological agents, which brought about a significant improvement of 40 
the life expectancy of melanoma patients. Once the gold standard (Avril et al., 2004), 41 
Dacarbazine-based chemoterapies are still approved and widely applied in melanoma therapy, 42 
but their efficacy is known to be relatively low (Garbe et al., 2011). In the light of this, the 43 
fact that clinical improvement was observed quite early during the chemotherapy suggested 44 
other factors behind the outcome, and the concurrent sepsis seemed to offer a potential 45 
explanation.   46 
It has long been recognized that cancer patients might recover following bacterial 47 
infections (Wiemann and Starnes, 1994; Hobohm, 2001). The hypothesis was that fever and 48 
TNF-α induced by the infectious agents caused the tumor regression, but this could not be 49 
reproduced by TNF-α administration or hyperthermia (Nauts et al., 1946; Tsung and Norton, 50 
2006). It has been observed that an attenuated form of Listeria monocytogenes can infect 51 
cancer cells, but not normal cells, and this phenomenon resulted in a potentially effective 52 
experimental cancer therapy. (Quispe-Tintaya W et al.2013) 53 
































































Vaccination with intracellular pathogens like Bacillus Calmette-Guerin or Vaccinia 54 
virus significantly decreased the incidence of melanoma (Krone et al., 2005). However, a 55 
convincing explanation is still missing. 56 
While it is generally accepted that anti-tumor immune mechanisms overlap with anti-57 
bacterial immune responses (Chen et al., 2007; Adams, 2009;), the exact mechanism induced 58 
by microbes is not understood. 59 
As immune responses appear to be decisive factors also in the outcome of melanoma 60 
(Ridnour et al., 2013; Shimanovsky et al., 2013), we hypothesized that sepsis, by triggering 61 
polarized, “joint” anti-bacterial and anti-tumor immune responses, could induce tumor 62 
regression. This hypothesis was tested in our experimental model.  63 
To clarify the role of the adaptive immune system in the anti-tumor immune 64 
mechanisms induced by C. pneumoniae (CP, successfully identified in the primary melanoma 65 
after our patient recovered from sepsis-Suppl. Fig. 1f), lung metastases (LM) were induced in 66 
immunocompetent C57BL/6 mice or immunodeficient NSG mice. Animals were then CP- or 67 
mock-treated (Suppl. Materials and methods). To assess the effects of treatment, histological, 68 
immunological and molecular analyses were done.  69 
 70 
Results 71 
In immunocompetent, CP- treated animals, the number of LMs significantly decreased 72 
(P=0.003) (Fig. 1a), while the survival (Fig. 1t) significantly increased (P=0.04) compared to 73 
mock treatment. This was not observed in immunodeficient mice, and the treated animals did 74 
not develop fever (33.2 ºC±1.0 mock vs. 34.8 ºC±0.5 CP) or high plasma levels of TNF-α 75 
either, which is against the “fever hypothesis” (Wiemann and Starnes, 1994; Hobohm, 2001). 76 
Histological analysis of slices from the lungs of mock-treated melanoma-bearing 77 
immunocompetent mice showed a high number of LMs, with frequent intra-tumor necrosis 78 
































































(Fig. 1e). In contrast, fewer and smaller foci of regressive LMs were observed in the CP-79 
treated immunocompetent animals (Fig. 1f). Moreover, in this group, a high number of tumor-80 
infiltrating mononuclear histiocytes and lymphoid cells were identified in the LMs. The LMs 81 
did not exhibit significant intratumor immune reactions in the immunodeficient mice, 82 
regardless of treatment type (Fig. 1g, h). Markedly increased immune reaction in the lungs of 83 
the CP-treated mice was also verified by immunolabeling of the cell surface activation 84 
markers CD11b and CD80 (Fig. 1i-l).  Immune cell invasion was not detected after mock 85 
treatment - the immune cells were concentrated in the marginal zones of the tumors (Fig. 1i, 86 
k). In contrast, after CP treatment, marked infiltration by activated lymphocytes was seen in 87 
the internal tumor stroma (Fig. 1j, l); differences were significant (Fig. 1m, n) (P=0.0001). 88 
To assess macrophage polarization, M1 (anti-tumor) or M2 (pro-tumor) macrophage - 89 
specific cytokine and chemokine transcriptome profiling was done (Mantovani et al., 2004). 90 
Macrophage markers were detected with Q-PCR from pooled lung samples 2, 4 and 12 hours 91 
after mock or CP treatment. Four hours after CP application, markedly increased levels of M1 92 
- specific mRNA transcripts for CCL2, CCL3, IL6, CXCL10, CCL7, CD80, CXCL11, 93 
CXCL9, IL23, and TNFα were detected. In line with this, the mRNA expression of most M2-94 
specific markers decreased. Interestingly, the levels of some important M2 markers 95 
(CXCL13, IL1Ra) were actually increased (Suppl. Fig. 2a, b). Upon CP administration, the 96 
quantity of M1-specific cytokine and chemokine mRNA was significantly increased 97 
(P=0.014) after 4 hours, in comparison to M2- markers. 98 
Alteration in the expression pattern of COX-1 and COX-2 is one of the key markers of 99 
macrophage polarization (Martinez et al., 2006; Mantovani et al., 2013). Western blot 100 
analysis revealed that 12 hours after CP treatment, protein expression of the M2-specific 101 
COX-1 decreased by half, whereas the protein expression of the M1-specific COX-2 102 
increased more than two fold (Suppl. Fig. 2c, d). 103 
































































Two hours after CP treatment -but not after mock treatment- CXCL1 melanoma 104 
growth factor immunoreactivity become undetectable (Suppl. Fig. 3a, b). To assess whether 105 
this in vivo phenomenon was due to a direct CP:CXCL1 interaction, equal amounts of 106 
recombinant CXCL1 were incubated in vitro (in the presence of protease inhibitors) with 107 
increasing quantities of CP. CXCL1 levels were determined by Western blotting. CP depleted 108 
CXCL1 in a dose-dependent manner, suggesting a strong and direct binding by CP (Suppl. 109 
Fig. 3c, d). 110 
Discussion 111 
Our results seem to indicate that CP treatment does indeed induce a complex anti-tumor 112 
response. We showed that CP treatment can suppress LM formation in immunocompetent 113 
(but not in immunodeficient) mice. M1-type macrophage polarization was demonstrated, 114 
which is associated with anti-tumor effects (Sica et al., 2008). The anti-tumor immune 115 
polarization/activation was further supported by the profound enrichment of CD80 and 116 
CD11b expressing immune cells in the lungs CP- treated animals (Prebeck et al., 2001). Of 117 
special importance, the melanoma growth factor CXCL1 was completely depleted by CP, 118 
both in vivo and in vitro. 119 
As (i) CXCL1-induced NF-κB activity was shown to facilitate melanoma transformation by 120 
allowing melanocytes to escape apoptosis; and (ii) IκB-α ∆N (super-repressor of NF-κB) 121 
reduced tumor growth and metastatic potential of melanoma cells (Dhawan et al., 2002), we 122 
consider it a possible scenario that not only the CP induced M1 type macrophage polarization 123 
but the induced CXCL1 depletion could significantly contribute to the tumor regression. 124 
Evidently, results of the animal study strongly support our assumption about the role of sepsis 125 
in the observed outcome; however, these data cannot exclude the role of the  BOLD therapy. 126 
The conclusion one can safely draw at this point is that sepsis, in the context of BOLD, 127 
































































resulted in a dramatic improvement, otherwise not seen in uncomplicated therapy, which 128 
suggests that the occurrence of sepsis was an event of key importance.  129 
 130 
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Table 1: Timeline of Clinical Case Report 195 
day  
-360 The patient herself detected a bleeding nevus-like lesion on the back and an enlarged axillary lymph node; no 
steps were taken. 
120 Hospital visit. X-ray, mammography and abdominal doppler seems to be negative, axillary lymph node biopsy 
was proposed. The patient was temporarily lost from follow up. 
0 Hospital visit for abdominal pain, gastritis was diagnosed and a gastric polyp was removed. Tumor 
masses were discovered in the retroperitoneal lymph nodes (15-20 mm), spleen (67 mm) and bladder 
(40x68 mm). Another tumor was detected in the brain by CT (40 mm).  
4 The intracranial tumor mass was removed surgically and diagnosed as amelanotic melanoma metastasis. 
24 Cranial radiotherapy was initiated. 
30 Leukocytosis, fever. Amoxicillin+clavulanic acid treatment. 
32 Radiotherapy completed. 
35 BOLD (bleomycin, oncovine, lomustine and dacarbazine) chemotherapy initiated.  
37 On the 3rd day of chemotherapy, it was suspended because of vomiting and fever. The gastric fluid contained 
Escherichia coli and Candida albicans. Clostridium difficile toxin was also detected. Fluconazole and 
ceftriaxone (later metronidazol) treatment was initiated. 
52 CVC was removed because of putative Pseudomonas aeruginosa infection. This was later confirmed by blood 
test.  
59 The primary tumor was excised and analyzed (Melanoma malignum, Br 1.52 mm, C1. III., pT2b). 
77 BOLD, 2nd treatment cycle. Decrease of axillary and abdominal metastases was detected. 
120 BOLD, 3rd cycle. Further improvement of the axillary and intra-abdominal metastases was recorded. No intra-
abdominal lympadenomegalia, a single liver metastasis and shrinking splenic metastasis was detected. 
162 BOLD, 4th cycle. Complete remission of the axillary and abdominal metastases was observed. 
210 BOLD, 5th cycle. Complete remission of the axillary and abdominal metastases was observed. 
255 BOLD, 6th cycle. The patient is asymptomatic and PET/CT-verified metastases free. 
>1500 The patient is asymptomatic and PET/CT-verified metastases free. 
 196 
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Figure 1:  198 
C. pneumoniae treatment results in melanoma metastasis regression and increases 199 
survival of animals as well as of CD11b+ and CD80+ immune cell infiltration of tumor 200 
tissues 201 
Number of lung metastases (a, c), melanoma antigen-MART (b, d) and survival rate (t) of 202 
mock or C. pneumoniae (C. pn.) treated immunocompetent C57BL/6 and immundeficient 203 
NSG mice. Representative images and HE-stained histological sections of dissected lungs of 204 
mock (e) and C. pneumoniae (f) treated immunocompetent mice, as well as of mock (g) and 205 
C. pneumoniae (h) treated immunodeficient (NSG) animals. Note that the subpleural 206 
metastasis formation is extensive in diameter but not in thickness in NSG mice (arrowheads). 207 
Scale bars, 100 µm. (e) Trophical necroses indicating high tumor burden. Insert: atypical 208 
tumor cells and regions of necrosis. (f) Circles and right insert, foci of regressive metastases, 209 
left insert: areas of residual pneumonitis after C. pneumoniae treatment. (g, h) In both mock 210 
and C. pneumoniae treated NSG mice, miliary metastases were developed subpleurally 211 
(arrowheads) and intraparenchymally (circles) without significant inflammatory reactions 212 
(inserts: higher magnification of intraparenchymal metastases). Immunohistochemistry of 213 
CD11b (i, j, DAB, brown) and CD80 (k, l, Fast red, red) on lungs of mock (i, k) or C. 214 
pneumoniae (j, l) treated C57BL/6 mice. Dashed lines indicate tumor border. (i-r) Arrows 215 
indicate infiltrating immune cells. Intratumoral number of CD11b+ (m) and CD80+ (n) cells 216 
determined as a ratio of 100 tumor cells in C57BL/6 mice. CD80+ cells in NSG lungs counted 217 
by square millimeter (s). Data are given as mean ± SD. 218 
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Number of lung metastases (a, c), melanoma antigen-MART (b, d) and survival rate (t) of mock or C. 
pneumoniae (C. pn.) treated immunocompetent C57BL/6 and immundeficient NSG mice. Representative 
images and HE-stained histological sections of dissected lungs of mock (e) and C. pneumoniae (f) treated 
immunocompetent mice, as well as of mock (g) and C. pneumoniae (h) treated immunodeficient (NSG) 
animals. Note that the subpleural metastasis formation is extensive in diameter but not in thickness in NSG 
mice (arrowheads). Scale bars, 100 µm. (e) Trophical necroses indicating high tumor burden. Insert: 
atypical tumor cells and regions of necrosis. (f) Circles and right insert, foci of regressive metastases, left 
insert: areas of residual pneumonitis after C. pneumoniae treatment. (g, h) In both mock and C. 
pneumoniae treated NSG mice, miliary metastases were developed subpleurally (arrowheads) and 
intraparenchymally (circles) without significant inflammatory reactions (inserts: higher magnification of 
intraparenchymal metastases). Immunohistochemistry of CD11b (i, j, DAB, brown) and CD80 (k, l, Fast red, 
red) on lungs of mock (i, k) or C. pneumoniae (j, l) treated C57BL/6 mice. Dashed lines indicate tumor 
border. (i-r) Arrows indicate infiltrating immune cells. Intratumoral number of CD11b+ (m) and CD80+ (n) 






























































cells determined as a ratio of 100 tumor cells in C57BL/6 mice. CD80+ cells in NSG lungs counted by square 
millimeter (s). Data are given as mean ± SD.  
173x257mm (300 x 300 DPI)  
 
 
































































Supplementary Discussion:  
The blots of the Proteome Profiler (Suppl. Fig. 3a, b) in the upper left lower left and lower 
right positions are the so-called assay controls, they merely indicate that the test was 
technically successful. The rest of the proteins –which could be relevant in the anti-tumoral 
immune response-are as follows (from left to right and from top to bottom):  C5a, CD54, 
CXCL1, MCP-1, IL-16, IL-1Ra, CCL5. 
- C5a is a complement protein that has been implicated in tumorigenesis. C5a accelerates 
tumor progression, can directly activate myeloid-derived suppressor cells, stimulate 
angiogenesis and cell migration. C5a increases VEGF level, prevents the activation of 
apoptotic caspase 3 and DNA fragmentation, and may function as an anti-apoptotic molecule 
(Kim et al., 2005; Gunn et al., 2012). We found decreased levels of this protein after 
treatment. 
- CD54 (ICAM-1) decreased in our in vivo model and expresses with a dose- and time-
dependent increase in human malignant melanoma cells on stimulation of TNF-alpha. 
Inhibition of ICAM-1 expression on melanoma cells reduces the metastatic ability of the 
melanoma cells, indicating an important role of ICAM-1 in metastasis (Miele et al., 1994). B. 
Cava et al. described that metastasis reduction of B16 cells is correlated to the reduction of 
plasma gelatinolitic activity and to the decrease of cells expressing CD44, CD54, and 
integrin-β3 adhesion molecules. 
- CXCL1 is a melanoma growth factor and known as M2 marker. Our results suggest that the 
depletion of CXCL1 could play a role in the reduction of metastasis formation.  
- MCP-1 (decreased in our model) is produced by a variety of tumors, including B16F1 and 
plays an important role in tumor progression, especially in angiogenesis (Kim et al., 2005; 
Koga et al., 2008). Tumor cell-activated macrophages release TNFα, which facilitates the 
































































MCP-1 production of tumor cells. Thus, disruption of tumor-stromal cell interaction may 
inhibit tumor progression by reducing the production of tumor-promoting proinflammatory 
mediators, such as MCP-1 (Yoshimura et al., 2015). 
- IL-16: it is a pleiotropic cytokine that functions as a chemoattractant, hence a modulator of 
T cell activation. The cytokine function is exclusively attributed to the secreted C-terminal 
peptide, while the N-terminal product may play a role in cell cycle control. Caspase 3 is 
reported to be involved in the proteolytic processing of this protein 
(http://www.cancerindex.org/geneweb/IL16.htm).  IL-16 appears in the literature remarkably 
scarcely in connection with cancer, and we could not detect alteration in its level either; 
therefore, we do not know the relevance of this protein  to the discussed observation.  
- IL-1Ra (moderately decreased or unchanged in our model) is the receptor antagonist of IL-1 
and it has been described as pleiotropic (Aubie et al., 2015; Di Mitri et al., 2014).  Although 
IL-1Ra has been described to inhibit subcutaneus B16 melanoma growth in vivo (McKenzie et 
al., 1996) we did not observe significant changes in its level upon treatment; therefore, similar 
to IL-16, the relevance of this finding is still unknown.  
- CCL5 (decreased in our model) is a chemokine with tumor supportive properties (Adler et 
al., 2003; Sugasawa et al., 2008). In rectal cancer, significant decrease of CCL5 was 
associated with a favorable response to chemoradiation therapy (Tada et al., 2014). Moreover, 
Mdr2 and CCR5 (CCL5 receptor) double knock-out mice exhibited significant decrease in 
tumor incidence and size of hepatocellular carcinoma (Barashi et al., 2013). Finally, CCL5 




































































Supplementary Materials and methods 
The mouse model 
B16F1 melanoma cells (ECACC, Salisbury, UK) were administered intravenously (1x10
5
 
cell/100 µl) to 6-8 week old female immunocompetent C57BL/6 or immuno-deficient 
NOD/Scid IL2rg null (NSG) mice (Charles River Laboratories, Budapest, Hungary). One 
week after the tumor cell administration, mice were treated with C. pneumoniae strain CWL-
029 (VR-029, ATCC, Wesel, Germany) propagated in Hep2 cells (CCL-23, ATCC, Wesel, 
Germany) (Mantovani et al., 2004). C. pneumoniae and the mock control (processed Hep2 
cells) were heat-inactivated at 90˚C for 30 minutes. Mice were mildly sedated with sodium 
pentobarbital (7.5 mg/ml) and treated intranasally with 1×10
6
 IFU C. pneumoniae 7, 9, 11, 14, 
and 16 days after tumor implantation. In the case of immune-deficient mice, since physical 
conditions of NSG mice deteriorated extremely rapidly, animals were euthanized at day 14 
after the third C. pneumoniae treatment. The special advantages of this model are: (i) with 
intravenous injection of melanoma cells, visible lung tumor metastases develop within 7 days 
after injection without significant spreading into other organs; and (ii) C. pneumoniae is a 
lung-specific intracellular pathogen with a significant invasion rate even to the lung 
metastases. Two hours after the 1
st
 inhalation (day 7), 4 hours after 2
nd
, 12 hours after 3
rd
 and 
24 hours after 5
th
 inhalation, 3 animals/group were anaesthetized and their lungs were 
harvested for protein, mRNA and histological analysis. The remaining mice received the 4
th
 
(day 14) and the 5
th
 (day 16) treatments and were followed for survival. At the end-point, the 
animals were euthanized, their lungs were removed and 3 independent persons counted the 
number of surface metastases in a blind fashion. 
 All animal experiments were performed in accordance with national (1998. XXVIII; 
40/2013) and European (2010/63/EU) animal ethics guidelines. The experimental protocols 
were approved by the Animal Experimentation and Ethics Committee of the Biological 
































































Research Centre of the Hungarian Academy of Sciences and the Hungarian National Animal 
Experimentation and Ethics Board (clearance number: XVI./03521/2011.). Informed consent 
was obtained from all subjects. 
 
Survival 
For the survival experiments, groups of mice (n=15) were treated as described 5 times after 
melanoma implantation. Kaplan-Meier survival curves were analyzed by a log-rank statistical 
test and p ≤ 0.05 was regarded as statistically significant. The body temperatures of 3 
animals/group were measured using an AMA Digital AD 15 TH thermometer 2 hours after 
the 1
st
 treatment and 4 hours after the 2
nd
 inhalation (day 7 and 9). All animal experiments 
were authorized by the institutional and national animal welfare committees. 
 
Cytokine and Chemokine Expression Analysis by Quantitative Real-time PCR 
Total RNA was purified using a NucleoSpin RNA II RNA isolation kit (Macherey-Nagel, 
Düren, Germany); first-strand cDNA was synthesized and Q-PCR reactions were performed 
of M1 type (CCL2, CCL3, CD86, IL12, IL6, IL10, CXCL16, CCL7, CD80, CXCL11, 
CXCL9, IL23, TNFα) and M2 type (CD163, CXCL13, TGFβ, IL1Ra, CD23, CCL1, CCL22, 
IL4, CCL17, CCL24, CD150, IL10, CXCL1) markers on pooled samples (n=3) on a 
RotorGene 3000 instrument (Corbett Research) with gene-specific primers and SYBR Green 
protocol to monitor gene expression. Each individual Ct value was normalized to the average 
Ct values of four internal control genes (∆Ct values). The final relative gene expression ratios 
(fold change) were calculated as comparisons of ∆Ct values (∆∆Ct values). Non-template 
control sample was used for each PCR run to check the primer-dimer formation. Primer 
sequences are available upon request. 
 
































































C. pneumoniae detection from the primary tumor of patient by PCR 
DNA was extracted from the formalin fixed paraffin-embedded (FFPE) samples using 
Nucleospin® FFPE DNA kit (Macherey-Nagel, Düren, Germany) according to the 
manufacturer’s instruction. For experiments involving a human subject were performed in 
accordance with National and Regional Ethics Comitte VI-R-039/01840-2/2012; 
25363/2012/EKU; 448/PI/2012. The experimental protocols were approved by the National 
and Regional Ethics Comitte (clearance number: MCC-INTER-001.) 
 
Histology, immunohistochemistry 
Lung specimens were fixed in 4% buffered formaldehyde; then routine HE histology as wells 
as standardized immunohistochemistry tissue microarray were performed using anti-CD11b 
(clone M1/70; R&D Systems, Minneapolis, MN) and CD80 (B7-1; R&D Systems, 
Minneapolis, MN) antibodies. 
 
Cytokine and chemokine detection by proteome profiling  
Expression levels of different cytokines in pooled lung specimens were determined using 
Mouse Cytokine Array Panel A (R&D Systems, Minneapolis, MN), according to the 
manufacturer’s instructions. 
 
Western blot analysis of COX-1 and COX-2 
To determine COX-1/COX-2 balance, Western blot analysis was performed using the lung 
lysates. Samples of total proteins were resolved on NuPAGE 4-12% Bis-Tris Gel, and then 
transfered to a nitrocellulose membrane. The membrane was incubated with anti-COX-1 
(1:250, R&D, Minneapolis, MN) mouse monoclonal antibody and anti-COX-2 (1:200, R&D, 
Minneapolis, MN) goat polyclonal antibody. After overnight incubation, the membranes were 
































































washed with 1 x TRIS Buffer supplemented with 0,05% Tween20 (Sigma, St. Louis, MO) 
and incubated for one hour with peroxidase conjugated anti-mouse (1:1000, R&D, 
Minneapolis, MN) and anti-goat IgG (1:10000, Sigma, St. Louis, MO) and developed using 
Odyssey Fc chemiluminescence detection system (LiCor Bioscience, Lincoln, NE). 
 
Western blot analysis of CXCL1 
Recombinant mouse CXCL1 protein (0.5 µg, R&D Systems, Minneapolis, MN) was mixed 
and incubated (37°C, 30 min) with different 10-fold (10-10000) dilutions of C. pneumoniae 
solutions (3.6 µg-0.00036 µg). CXCL1 protein amounts were then detected by Western blot 
analysis using an anti-CXCL1 antibody (1:1000, R&D Systems, Minneapolis, MN). 
 
Statistical analysis 
Kaplan-Meier survival curves were analyzed by a log-rank statistical test and p ≤ 0.05 was 
regarded as statistically significant. Analyses of other data were performed using two-tailed 
Student’s t test. 
  
































































Supplementary Figure 1:  
Data obtained with the patient: Complete melanoma metastasis regression verified by 
PET-CT and retrospective PCR analysis-based detection of C. pneumoniae 
(a, b) Ultrasonography; high tumor burden in the abdominal cavity. (c, d) CT and MRI scans; 
preoperational brain metastasis in the temporooccipital lobe and postoperational tumor-free 
brain status, respectively. (e) PET-CT scans; complete tumor regression in the body shortly 
after the septic event and BOLD treatment. (f) Retrospective detection of C. pneumoniae (C. 
pn.)-specific genes by RT-PCR. 16S rRNA: a housekeeping gene of C. pn. GroEL: Heat 
shock protein 60 of C. pn., a group I chaperonin expressed on the surface of elementary 
bodies. MOMP: Major Outer Membrane Protein gene of C. pn. A-D: FFPE samples from 
different sections of primary melanoma; -C: PCR negative control (uninfected Hep2 cells); 
+C: PCR positive control (Hep2 cells infected by C. pn. strain TW183).  
  
Supplementary Figure 2: 
C. pneumoniae treatment induces M1 type macrophage polarization  
(a) Relative alterations in the levels of individual M1 type and M2 type cytokine/chemokine 
specific mRNA transcripts in lung samples of C. pneumoniae (C. pn.) vs. mock-treated tumor-
bearing C57BL/6 mice, as determined by real-time PCR. (b) Mean values of relative M1 and 
M2 cytokine mRNA expressions; at 4 hours after treatment, M1 and M2 levels are 
significantly different (two-tailed t-test). (c) Representative Western blot. Expressions of 
COX-1 and COX-2 were determined in lung samples 12 hours after C. pneumoniae or mock 
treatment of melanoma-bearing C57BL/6 mice (d) Densitometry analysis. Intensity of 
immunoreactive bands of COX-1 and COX-2 were determined and then normalized to that of 
































































vinculin. Data are presented as fold increase compared to values of the mock-treated group 
(regarded as 1). A minimum of three experiments yielded similar results. 
Supplamentary Figure 3:  
CXCL1 is depleted by C. pneumoniae both in vivo and in vitro 
Assessment of cytokine/chemokine protein levels (Proteome profiler) in lungs of melanoma-
bearing C57BL/6 mice 2 hours after mock (a) or C. pneumoniae (b) treatment. Squares 
indicate CXCL1 which disappeared 2 hours after C. pneumoniae treatment (c) Representative 
Western blot. Recombinant mouse CXCL1 protein (0.5 µg) was in vitro incubated with 500 
IUFU/µl (1x) C. pneumoniae, (C. pn.) or its 10x, 100x, 1,000x, and 10,000x dilutions and 
then Western blotting was performed. (d) Densitometry analysis of immunoreactive bands 
shown in panel c. Values of the control (ctrl, vehicle treated) group were regarded as 1. Two 
experiments yielded similar results. 
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Data obtained with the patient: Complete melanoma metastasis regression verified by PET-CT and 
retrospective PCR analysis-based detection of C. pneumoniae 
(a, b) Ultrasonography; high tumor burden in the abdominal cavity. (c, d) CT and MRI scans; preoperational 
brain metastasis in the temporooccipital lobe and postoperational tumor-free brain status, respectively. (e) 
PET-CT scans; complete tumor regression in the body shortly after the septic event and BOLD treatment. (f) 
Retrospective detection of C. pneumoniae (C. pn.)-specific genes by RT-PCR. 16S rRNA: a housekeeping 
gene of C. pn. GroEL: Heat shock protein 60 of C. pn., a group I chaperonin expressed on the surface of 
elementary bodies. MOMP: Major Outer Membrane Protein gene of C. pn. A-D: FFPE samples from different 
sections of primary melanoma; -C: PCR negative control (uninfected Hep2 cells); +C: PCR positive control 
(Hep2 cells infected by C. pn. strain TW183).  
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C. pneumoniae treatment induces M1 type macrophage polarization  
(a) Relative alterations in the levels of individual M1 type and M2 type cytokine/chemokine specific mRNA 
transcripts in lung samples of C. pneumoniae (C. pn.) vs. mock-treated tumor-bearing C57BL/6 mice, as 
determined by real-time PCR. (b) Mean values of relative M1 and M2 cytokine mRNA expressions; at 4 hours 
after treatment, M1 and M2 levels are significantly different (two-tailed t-test). (c) Representative Western 
blot. Expressions of COX-1 and COX-2 were determined in lung samples 12 hours after C. pneumoniae or 
mock treatment of melanoma-bearing C57BL/6 mice (d) Densitometry analysis. Intensity of immunoreactive 
bands of COX-1 and COX-2 were determined and then normalized to that of vinculin. Data are presented as 
fold increase compared to values of the mock-treated group (regarded as 1). A minimum of three 
experiments yielded similar results. 
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CXCL1 is depleted by C. pneumoniae both in vivo and in vitro 
Assessment of cytokine/chemokine protein levels (Proteome profiler) in lungs of melanoma-bearing C57BL/6 
mice 2 hours after mock (a) or C. pneumoniae (b) treatment. Squares indicate CXCL1 which disappeared 2 
hours after C. pneumoniae treatment (c) Representative Western blot. Recombinant mouse CXCL1 protein 
(0.5 µg) was in vitro incubated with 500 IUFU/µl (1x) C. pneumoniae, (C. pn.) or its 10x, 100x, 1,000x, and 
10,000x dilutions and then Western blotting was performed. (d) Densitometry analysis of immunoreactive 
bands shown in panel c. Values of the control (ctrl, vehicle treated) group were regarded as 1. Two 
experiments yielded similar results. 
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intended audience.
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. The material will not be used out of context.
. My name will not be published. I understand, however, that complete
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appear.
. If I decide at any time before publication to withdraw consent, the clinical
information and relevant identifying materials will be destroyed.
Signed: "G . , ta^ o anrl Date 01/2612015
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Dear Prof. Gilchrest, 
 
We apologize for the inconvenience we caused. Indeed, it was our mistake that we 
mixed up the figure legends in the submission process, and we also agree that the arrows in 
the mentioned figure might be misleading. 
 
We have corrected these mistakes, but no other changes (either in formatting or 
content-wise) have been made as compared to the version that had previously been accepted 
by the Reviewers.  
The following corrections have been made: 
1. The Figure legends that belongs to Supplementary Figure 3. has been corrected to 
reflect which is actually in the figure. 
2. The arrows in panel b. have been removed from CD54 and CCL5, as requested. 
 
We would also like to express our gratitude for Your kind patience and for having 
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